Statin therapy for Alzheimer's disease. Will it work?

S. S. Petanceska, S. DeRosa, V. Olm, N. Diaz, A. Sharma, T. Thomas-Bryant, K. Duff, Miguel Pappolla, L. M. Refolo

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Disease-modifying therapies are being developed for Alzheimer's disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer's amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.

Original languageEnglish (US)
Pages (from-to)155-161
Number of pages7
JournalJournal of Molecular Neuroscience
Volume19
Issue number1-2
StatePublished - Aug 2002
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Alzheimer Disease
Cholesterol
Amyloidosis
Therapeutics
Animal Models
Brain
Amyloid
Transgenic Mice
Coronary Disease
Disease Progression
Animals
Epidemiologic Studies
Randomized Controlled Trials
Biomarkers
Placebos
Pathology
Phenotype
Peptides
Metabolism

Keywords

  • Amyloid
  • Animal model
  • Cholesterol
  • Statin
  • Therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry
  • Genetics

Cite this

Petanceska, S. S., DeRosa, S., Olm, V., Diaz, N., Sharma, A., Thomas-Bryant, T., ... Refolo, L. M. (2002). Statin therapy for Alzheimer's disease. Will it work? Journal of Molecular Neuroscience, 19(1-2), 155-161.

Statin therapy for Alzheimer's disease. Will it work? / Petanceska, S. S.; DeRosa, S.; Olm, V.; Diaz, N.; Sharma, A.; Thomas-Bryant, T.; Duff, K.; Pappolla, Miguel; Refolo, L. M.

In: Journal of Molecular Neuroscience, Vol. 19, No. 1-2, 08.2002, p. 155-161.

Research output: Contribution to journalArticle

Petanceska, SS, DeRosa, S, Olm, V, Diaz, N, Sharma, A, Thomas-Bryant, T, Duff, K, Pappolla, M & Refolo, LM 2002, 'Statin therapy for Alzheimer's disease. Will it work?', Journal of Molecular Neuroscience, vol. 19, no. 1-2, pp. 155-161.
Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T et al. Statin therapy for Alzheimer's disease. Will it work? Journal of Molecular Neuroscience. 2002 Aug;19(1-2):155-161.
Petanceska, S. S. ; DeRosa, S. ; Olm, V. ; Diaz, N. ; Sharma, A. ; Thomas-Bryant, T. ; Duff, K. ; Pappolla, Miguel ; Refolo, L. M. / Statin therapy for Alzheimer's disease. Will it work?. In: Journal of Molecular Neuroscience. 2002 ; Vol. 19, No. 1-2. pp. 155-161.
@article{1a01d462134943b290d4ce7033d6bcf0,
title = "Statin therapy for Alzheimer's disease. Will it work?",
abstract = "Disease-modifying therapies are being developed for Alzheimer's disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer's amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.",
keywords = "Amyloid, Animal model, Cholesterol, Statin, Therapy",
author = "Petanceska, {S. S.} and S. DeRosa and V. Olm and N. Diaz and A. Sharma and T. Thomas-Bryant and K. Duff and Miguel Pappolla and Refolo, {L. M.}",
year = "2002",
month = "8",
language = "English (US)",
volume = "19",
pages = "155--161",
journal = "Journal of Molecular Neuroscience",
issn = "0895-8696",
publisher = "Humana Press",
number = "1-2",

}

TY - JOUR

T1 - Statin therapy for Alzheimer's disease. Will it work?

AU - Petanceska, S. S.

AU - DeRosa, S.

AU - Olm, V.

AU - Diaz, N.

AU - Sharma, A.

AU - Thomas-Bryant, T.

AU - Duff, K.

AU - Pappolla, Miguel

AU - Refolo, L. M.

PY - 2002/8

Y1 - 2002/8

N2 - Disease-modifying therapies are being developed for Alzheimer's disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer's amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.

AB - Disease-modifying therapies are being developed for Alzheimer's disease (AD). These are expected to slow the clinical progression of the disease or delay its onset. Cerebral accumulation of amyloid β (Aβ) peptides is an early and perhaps necessary event for establishing AD pathology. Consequently therapies aimed at attenuating brain amyloidosis are expected to be disease modifying. Based on the epidemiological evidence pointing to a link between cholesterol metabolism and AD and the numerous laboratory studies implicating cholesterol in the process of Aβ production and accumulation, it is now believed that cholesterol-lowering therapies will be of value as disease modifying agents. Several epidemiological studies revealed that statin use for the treatment of coronary arterial disease is associated with a decreased prevalence or a decreased risk of developing AD. These observations require both preclinical and clinical validation. The former involves testing statins in one or more animal models of AD in order to establish which disease features are affected by statin treatment, the relative efficacy with which different statins modify these features and the mechanism(s) by which statins affect AD phenotypes. The latter requires prospective, randomized, placebo controlled trials to evaluate the effect of statin treatment on cognitive and AD biomarker outcomes. We have initiated a study aimed at determining the effects of atorvastatin (LipitorR), a statin with the largest US market share, on brain Aβ deposition in the PSAPP transgenic mouse model of Alzheimer's amyloidosis. Our results indicate that Lipitor treatment markedly attenuates Aβ deposition in this animal model.

KW - Amyloid

KW - Animal model

KW - Cholesterol

KW - Statin

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0036672689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036672689&partnerID=8YFLogxK

M3 - Article

C2 - 12212773

AN - SCOPUS:0036672689

VL - 19

SP - 155

EP - 161

JO - Journal of Molecular Neuroscience

JF - Journal of Molecular Neuroscience

SN - 0895-8696

IS - 1-2

ER -